Philip V. Peplow – författare

This volume presents recent data on the latest achievements in new and emerging technologies for biomarkers and for innovations in their assessment. The chapters cover topics such as activation of microglia and macrophages in neurodegenerative diseases; oxidative stress and cellular dysfunction in neurodegenerative diseases; TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders; and imaging biomarkers in Huntington''s disease and amyotrophic lateral sclerosis. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and comprehensive, Neurodegenerative Diseases Biomarkers: Towards Translating Research to Clinical Practice is a valuable resource for both experimental and clinical experts in the field of neurodegenerative diseases who are looking to expand their knowledge of novel biomarkers in different types of neurodegenerative diseases.

A rise in the number of young and old patients suffering from a stroke or traumatic brain injury has led to the need for better drug development and treatment, as well as diagnosis and prevention of ischemic stroke and traumatic brain injury. This book provides a comprehensive overview of scientific advancements in these areas.

Chapters provide the latest knowledge in neuroscience, biotechnology, and personalized medicine applicable to acute brain injuries. Development of neuroprotective drugs is treated in detail. Chemical biomarkers for detection, imaging and preventative strategies are covered to provide medicinal chemists with a broad view of translational aspects of the field.

This book will be useful to postgraduate students and researchers in medicinal chemistry and pharmacology as well as specialists in the acute brain injury field.

A rise in the number of young and old patients suffering from a stroke or traumatic brain injury has led to the need for better drug development and treatment, as well as diagnosis and prevention of ischemic stroke and traumatic brain injury. This book provides a comprehensive overview of scientific advancements in these areas.

Chapters provide the latest knowledge in neuroscience, biotechnology, and personalized medicine applicable to acute brain injuries. Development of neuroprotective drugs is treated in detail. Chemical biomarkers for detection, imaging and preventative strategies are covered to provide medicinal chemists with a broad view of translational aspects of the field.

This book will be useful to postgraduate students and researchers in medicinal chemistry and pharmacology as well as specialists in the acute brain injury field.

From pathology to treatment, MicroRNAs in Diseases and Disorders highlights the role of microRNAs (miRNAs) in the development and progression of a variety of diseases, including cancer, neurological disease, endocrine disease and autoimmune disease, and underscores the utilization of miRNA targets in the treatment of these conditions. Providing a comprehensive account, this book also includes the identification of miRNAs as diagnostic and prognostic biomarkers for disease, as well as evaluates translational value from clinical trials using synthesized and functionalized miRNA mimics and inhibitors. With a global contribution list and chapters from leading experts across the field, MicroRNAs in Diseases and Disorders is an invaluable reference to miRNA researchers and health professionals in a variety of disease areas in government, academia and industry. The book will also appeal to pharmaceutical and medicinal chemists with an interest in miRNA targeting therapeutics, as well as to advanced students in chemical biology and drug discovery.

From pathology to treatment, MicroRNAs in Diseases and Disorders highlights the role of microRNAs (miRNAs) in the development and progression of a variety of diseases, including cancer, neurological disease, endocrine disease and autoimmune disease, and underscores the utilization of miRNA targets in the treatment of these conditions. Providing a comprehensive account, this book also includes the identification of miRNAs as diagnostic and prognostic biomarkers for disease, as well as evaluates translational value from clinical trials using synthesized and functionalized miRNA mimics and inhibitors. With a global contribution list and chapters from leading experts across the field, MicroRNAs in Diseases and Disorders is an invaluable reference to miRNA researchers and health professionals in a variety of disease areas in government, academia and industry. The book will also appeal to pharmaceutical and medicinal chemists with an interest in miRNA targeting therapeutics, as well as to advanced students in chemical biology and drug discovery.